LAS VEGAS–(BUSINESS WIRE)–#AngioVueEssential–Optovue will unveil its new AngioVue Essential OCTA capability for optometry and general ophthalmology at the International Vision Expo & Conference.
Category: Business
Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases
LEXINGTON, Mass & NEW YORK–(BUSINESS WIRE)–Inotek Pharmaceuticals (NASDAQ: ITEK) today announced that they have entered into a definitive merger agreement with Rocket Pharmaceuticals Ltd.
Acucela Granted New Patent Covering Method of Use for Emixustat Hydrochloride
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide, announced today that the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 9,737,496 B2 assigned to Acucela, adding strength to the company’s intellectu
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary endpoint has not been met in Spectri, the first of two Phase III studies evaluating the safety and effic…
Presbia to Participate in Rodman & Renshaw 19th Annual Global Investment Conference
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ:LENS), an ophthalmic device company and leader in near-vision restoration that has developed the Presbia Flexivue Microlens™, a proprietary optical lens implant for treating presbyopia, announced that Todd Cooper, President and CEO, is scheduled to present at the Rodman & Renshaw 19th Annual Investment Conference. The Conference will take place at the Lotte New York Palace Hotel in New York City from September 10 to 12, 2017. Mr. Cooper will be a
Presbia to Participate in Rodman & Renshaw 19th Annual Global Investment Conference
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ:LENS), an ophthalmic device company and leader in near-vision restoration that has developed the Presbia Flexivue Microlens™, a proprietary optical lens implant for treating presbyopia, announced that Todd Cooper, President and CEO, is scheduled to present at the Rodman & Renshaw 19th Annual Investment Conference. The Conference will take place at the Lotte New York Palace Hotel in New York City from September 10 to 12, 2017. Mr. Cooper will be a
Global Age-Related Macular Degeneration Market and Competitive Landscape 2017 – Research and Markets
DUBLIN–(BUSINESS WIRE)–The “Global Age-Related Macular Degeneration Market and Competitive Landscape – 2017” report has been added to Research and Markets’ offering. The latest research, Global Age-Related Macular Degeneration Market and Competitive …
Aerie Pharmaceuticals to Present at Two Investor Conferences in September
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that company management will present at the following conferences in September. Rodman & Renshaw 19th Annual Global Investment Conference (sponsored by H.C. Wainwright & Co., LLC) Presentation Date: Tuesday, Se
ReVision Optics Names Two Ophthalmic Experts as Medical Monitors to Oversee Raindrop Near Vision Inlay Clinical Performance
LAKE FOREST, Calif.–(BUSINESS WIRE)–ReVision Optics, Inc. (RVO), a leader in implantable presbyopia-correcting corneal inlay technology, announces that Bret Fisher, M.D. and Sumit (Sam) Garg, M.D. will serve as co-medical monitors to oversee the clinical performance of the Company’s Raindrop® Near Vision Inlay, a novel corneal inlay for the surgical correction of presbyopia approved by the U.S. Food and Drug Administration (FDA) in June 2016. Drs. Fisher and Garg are assuming the responsibili
Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
IRVINE , Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced the commencement of patient dosing in Mercury 3, the Company’s European Phase 3 clinical trial of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel onc
Kala Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals will present at the 12th Annual Wells Fargo Securities Healthcare Conference at the Westin Waterfront Hotel in Boston, MA.
Second Sight to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York on September 12th
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced that Dr. Robert Greenberg, Chairman, will host one-on-one meetings throughout the day with investors and present at the Rodman & Renshaw 19th Annual Global Investment Conference as follows: Date: Tuesday, September 12, 2017 Time: 1:45 p.m. Ea
Europe Dry Eye Market and Competitive Landscape 2017 – Research and Markets
DUBLIN–(BUSINESS WIRE)–The “Europe Dry Eye Market and Competitive Landscape – 2017” report has been added to Research and Markets’ offering. The latest research, Europe Dry Eye Market and Competitive Landscape – 2017, provides comprehensive insights …
Europe Diabetic Retinopathy Market and Competitive Landscape 2017 – Research and Markets
DUBLIN–(BUSINESS WIRE)–The “Europe Diabetic Retinopathy Market and Competitive Landscape – 2017” report has been added to Research and Markets’ offering. Europe Diabetic Retinopathy Market and Competitive Landscape – 2017, provides comprehensive insi…
Europe Age-Related Macular Degeneration Market and Competitive Landscape 2017 – Research and Markets
DUBLIN–(BUSINESS WIRE)–The “Europe Age-Related Macular Degeneration Market and Competitive Landscape – 2017” report has been added to Research and Markets’ offering. The latest research, Europe Age-Related Macular Degeneration Market and Competitive …
Nightstar Files Registration Statement For Proposed Initial Public Offering
LEXINGTON, Mass. & LONDON–(BUSINESS WIRE)–Nightstar Files Registration Statement For Proposed Initial Public Offering
U.S. Optical Instrument And Lens Market 2017 – Analysis And Forecast to 2025 – Research and Markets
DUBLIN–(BUSINESS WIRE)–The “U.S. Optical Instrument And Lens Market – Analysis And Forecast to 2025” report has been added to Research and Markets’ offering. The report provides an in-depth analysis of the U.S. optical instrument and lens market. It …
Most Physicians Lack Basic Knowledge of Resources to Treat Travelers Experiencing In-Flight Medical Emergencies
PEORIA, Ill.–(BUSINESS WIRE)–42% of physicians reported being asked to volunteer during in-flight medical emergencies but 87% reported little/no knowledge of procedures involved.
Second Sight Receives Conditional FDA Approval to Begin First Orion Human Clinical Study
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced that the Company has received conditional approval from the U.S. Food and Drug Administration (FDA) to begin the Orion™ Cortical Visual Prosthesis System (Orion) feasibility clinical study. The conditional approval allows two U.S. sites to enroll u
BioTime to Present Data at the Military Health System Research Symposium
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will be presenting one podium pres…